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Summary
Backround: Prostate cancer incidence has been increasing
in most developed countries in the absence of similar trends
in mortality, and with variable patterns in different areas of the
world.
Materials and methods: Trends in incidence and mortality
from prostate cancer for the period 1974-1994 were analysed
using data from the Cancer Registries of the Swiss Cantons of
Vaud and Neuchatel. Of 5,010 cases registered, 80% were
histologically or cytologically confirmed.
Results: Age-standardized incidence rates increased from
33.1 to 48.6 per 100,000 (+47%). The upward trends were
greater in the most recent calendar periods, and in the younger
age groups (+77% at age 45 to 54; +57% at age 55 to 64). In
contrast, mortality was stable, with an overall increase of only
3% in age-standardized rates (from 20.4 to 21.0 per 100,000),
due to some increase in men aged 65 or above. Consequently,
the incidence/mortality rate ratios increased from 1.6 in 1974-
1979 to 2.3 in 1990-1994. Five-year observed and relative
survivals increased from 26% to 41% and from 46% to 58%,
respectively. Ten-year observed and relative survival for cases
diagnosed in 1985-1989 were 19% and 42%, respectively.
Survival improvements were greater below age 75.
Conclusions: The pattern of trends in incidence, mortality
and survival confirms the influence of improved diagnosis of
prostate cancer over the last few years in this European
population. Still, while Swiss prostatic cancer mortality rates
are the highest in the world (20.3 per 100,000, world standard),
i.e., about 30% higher than in the United States, all races
combined, incidence rates are still half as much. On account
of the steady increase of prostate-specific antigen testing in
Switzerland, further incidence increases are likely.
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Over the last decade in the United States (US) and
Canada there has been a dramatic, and in several aspects,
unprecedented rise in incidence of prostate cancer, which
has become the first site of incidence in American men.
These upward trends have been observed in various age
groups, including the youngest ones, i.e., between 50 and
59 years, and were not reflected in changes in mortality,
which rose only moderately, mainly in the elderly [1-8].
These trends have been interpreted in terms of in-
creased awareness and surveillance of prostate cancer,
including rises in biopsies and transurethral resections
of the prostate (TURP) for the treatment of benign
prostatic hyperplasia. Possibly most important, serum
prostate-specific antigen (PSA) has been widely adopted
as test for screening and early diagnosis, particularly
after 1989 [9]. The increase was largely due to localized
and regional cancer, and led to substantial rise in radical
prostatectomies, which more than tripled between 1983
and 1989 in all SEER areas, although substantial geo-
graphic differences were evident also within the US [8].
Recent data from some areas in the US, however, show a
levelling off and a reversal of incidence trends, possibly
following the removal of many prevalent cases [5, 7, 10-
12]. No decline is as yet evident on mortality. There is
also some evidence that the rate of advanced cancer has
fallen in the early 1990s [10, 13].
Only scanty information on countries other than the
US is available. A comparison of incidence, survival and
mortality rates in Nordic countries in 1983-1987 showed
that mortality was similar (around 30 per 100,000) in all
countries, but incidence ranged from 48.9 per 100,000 in
Denmark to 82.6 per 100,000 in Sweden, pointing to the
existence of potential differences in diagnostic intensity
in various countries [14]. A study from the Netherlands
[15] showed a steady rise in mortality, particularly in the
elderly, and another from England and Wales [16] re-
ported only moderate upward trends in incidence over
the period 1971-1986 and in mortality over the period
1970-1990. An analysis of trends between 1957 and 1991
in Norway [17] showed a rise in age-adjusted incidence
rates from 26.3 to 46.6 per 100,000, in the absence of
major changes in slope over time, and a similar trend in
mortality. A levelling of death rates was observed from
the mid 1970s onwards [17]. In South Australia [18],
incidence of prostate cancer was approximately stable
between 1977 and 1989, but increased by over a third by
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Table 1. Basis of diagnosis for prostate cancer by calendar period. Vaud and Neuchatel Cantons, Switzerland, 1974-1994.
Basis of diagnosis
Histology and/or cytology
Autopsy finding
Clinical examination only
Total, all cases
Calendar period
1974-1979
No.
840
98
118
1056
(%)
(79.5)
(9.3)
(11.2)
(100.0)
1980-1984
No.
817
84
124
1025
(%)
(79.7)
(8.2)
(12.1)
(100.0)
1985-1989
No.
1122
69
138
1329
(%)
(84.4)
(5.2)
(10.4)
(100.0)
1990-1994
No.
1394
66
140
1600
(%)
(87.1)
(4.1)
(8.8)
(100.0)
1993. In the same period, there was only a moderate
increase in mortality. Similar trends were observed up to
1994 in New South Wales and other Australian States
[19], and were correlated with rising rates of PSA testing,
transurethral ultrasound, prostate biopsy, TURP and
prostatectomy.
Recent data on survival after prostate cancer diagno-
sis are available on few countries. Improvements have
been reported in the US, where relative five-year survival
in Whites rose from 63% in 1970-1973 to 88% in 1986-
1991 [20]. In approximately the same period survival
also improved, but to a lesser extent, in Nordic countries
(from below 50% to slightly above 60%) [17, 21, 22].
It is, therefore, interesting to consider trends in pros-
tate cancer incidence and mortality from other coun-
tries. Switzerland, in particular, has the highest death
certification rates from prostate cancer in the world, i.e.,
over 30% higher than the overall US rate, and hence the
highest rates in any white population worldwide [23].
Little is known, however, on the epidemiology of the
disease in this area of the world. We analysed, therefore,
incidence, mortality and survival data from the Cancer
Registries of the Swiss Cantons of Vaud and Neuchatel.
of the disease. Death certification numbers were abstracted from
registries provided by the Swiss Federal Statistical Office. All certified
deaths from prostatic cancer (ICD Eighth Revision, code 185) in the
populations of Vaud (« = 2152) and Neuchatel (n = 652) during the
period 1974-1994 were considered.
Age-standardized incidence and mortality rates were computed by
the direct method (on the world standard population) per 100,000
population for four subsequent calendar periods and age groups.
Information on survival is routinely integrated into the registry
data file from the official mortality statistics available yearly on
magnetic tape. As a further step, 'apparently' non deceased cases are
actively followed-up through the verification of their vital status from
registries of current residence. The vital status of each prostatic cancer
included in this analysis has been thus confirmed up to December
1996.
Using the product limit (maximum likelihood) [27] method, sur-
vival curves were defined for the whole series by calendar period and
age group; differences between subgroups were assessed by means of
the log-rank test [28]. Two-, five- and 10-year relative survival rates [29]
were computed, after allowance for the general lifetables of the cantons.
In order to describe the concurrent changes in PSA testing, the
major laboratories in the Cantons of Vaud and Neuchatel were asked
to provide the number of PSA examinations performed in the years
between 1985 and 1996.
Results
Materials and methods
Data presented in this report were abstracted from the Vaud and
Neuchatel Cancer Registries files, which include incident cases of
malignant neoplasms in the cantons [24, 25] whose populations,
according to the 1990 Census, were about 602,000 and 164,000
inhabitants, respectively. In these cantons, cancer registration systems
have been implemented since 1972, and population-based incidence
data have been available since 1974. The registries are tumour-based,
and multiple primaries in the same person are entered separately. Most
cases are registered repeatedly and from different institutions, thus
improving completeness and accuracy of registration. The basic infor-
mation available comprises sociodemographic characteristics of the
patient, primary site and histological type of the tumour according to
the standard International Classification of Diseases for Oncology
(ICD-O) [26], and date of diagnostic confirmation (histological or
clinical diagnosis). Active follow-up is recorded, and each subsequent
item of information concerning an already registered case is used to
complete the records of that patient.
The present series comprises a total of 5010 new malignant pri-
mary prostatic cancers (ICD-O topography: 185.9) [26] diagnosed
between 1974 and 1994 in the resident populations of Vaud (n = 3915)
and Neuchatel (n = 1095). The age range was 41-102 years (median
age, 75 years). No information was available on stage and on treatment
Table 1 gives the distribution of prostate cancers diag-
nosed between 1974 and 1994 according to diagnosic
modality and calendar period. There was a steady ten-
dency of histologically confirmed cases to increase (from
80% in 1974-1979 to 87% in 1990-1994), and of those
incidentally found only at autopsy or by clinical exami-
nation to decline.
Table 2 gives age-specific and overall crude and age-
standardized incidence rates of prostate cancer in sub-
sequent calendar periods. Substantial upward trends
were recorded, ranging from an increase of 77% in age
group 45-54 to one of 37% in age group 75 years and
above. All-age standardized incidence rates rose from 33
to 49 per 100,000 (+47%). The absolute number of cases
per year changed from an average of 176 in 1974-1979 to
320 in 1990-1994.
Corresponding figures for mortality are given in
Table 3. Standardized rates were stable, from 20.4 in
1974-1979 to 21.0 per 100,000 in 1990-1994 (+3%).
Whereas 7%-8% increases were observed in mortality
rates in the elderly (i.e., 65-74 and ^ 75 years), some
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Table 2. Incidence of prostate cancer per 100,000 man years by age
and period of diagnosis. Vaud and Neuchatel, Switzerland, 1974-1994.
Age group
45-54
55-64
65-74
Calendar period
1974-
1979
4.7
70.1
278.4
645.3
55.0
33.1
1980-
1984
4.4
66.8
295.9
727.6
63.7
35.2
1985-
1989
9.0
87.9
342.5
875.0
79.0
42.7
1990-
1994
8.3
110.3
424.2
882.6
89.0
48.6
Percent
change'
+76.6
+57.3
+52.4
+36.8
+61.8
+46.8
Crude rate (all ages)
Age-standardized b rate
Number of cases per year 176 205 266 320 +81.8
a
 From 1974-1979 to 1990-1994.
b
 Standardized on the world population.
Table 3. Death certification rates for prostate cancer per 100,000 man
years by age and period of diagnosis. Vaud and Neuchatel, Switzerland,
1974-1994.
In Figure 1, the increasing gap between incidence
and mortality three-year rates since 1983-1985 clearly
emerges. The later rise in the number of PSA tests
performed in the cantons of Vaud and Neuchatel is also
shown, from none in 1986-1988, to 2737 in 1989-1991,
and to 20,734 in 1992-1994. In 1996, at least 11,854 PSA
tests were reported.
Table 4 gives the two-, five- and 10-year observed and
relative survival rate of prostate cancers diagnosed in
the aforementioned periods. Observed five-year survival
at all ages improved, from 26.4% in prostate cancer
patients diagnosed in 1974-1979 to 41.4% in those diag-
nosed in 1990-1994. Survival increases were similar in
the age groups < 65 and 65-74 years, but were modest
above 75 years of age (from 27.3 to 30.1). Also two-year
and 10-year survival showed some amelioration and
relative survival rates were consistent with, but higher
than observed survival (Table 4). Ten-year relative sur-
vival increased from 26.4% in 1974-1979 cases to 42.2%
in 1985-1989 cases.
Calendar period
1974- 1980- 1985- 1990-
1979 1984 1989 1994
Percent
change"
Age group
45-54
55-64
65-74
Crude rate (all ages)
Age-standardizedb rate
Incidence/mortalityb rate
ratio
1.6
25.6
128.9
582.1
33.9
20.4
1.6
1.4
21.4
135.8
584.2
39.0
20.3
1.7
4.0
23.4
128.6
657.8
43.9
21.9
1.9
0.4
19.9
139.2
619.7
43.8
21.0
-75.0
-22.3
+8.0
+6.5
+29.2
+2.9
2.3 +43.8
Number of deaths per year 109 126 148 157 +44.0
a
 From 1974-1979 to 1990-1994.
b
 Standardized on the world population.
decline emerged in middle-age men, though based on
few deaths. Incidence-to-mortality rate ratios increased
from 1.6 to 2.3. Yearly number of deaths from cancer of
the prostate increased from an average of 109 to 157 in
1990-1994.
Discussion
The present report, one of the few available from Euro-
pean areas [14-17], confirms that also in this population
the incidence of prostate cancer has substantially in-
creased, particularly during the last decade and that -
in relative terms - the increase has been larger in men
below age 75 years. Five-year relative survival has also
increased from 46% to 58%, a change that cannot be
accounted for by changes in treatment [6, 9, 11]. Mor-
tality, in contrast, has been stable, with a modest rise
only in the elderly. In the mid 1970s there were 1.6 new
cases per each death from prostate cancer, whereas in
1990-1994 this ratio became 2.3.
While it is unlikely that these frequencies have been
appreciably affected by changes in completeness of can-
cer registration in these areas, which has not changed
over the period considered [24, 25], these trend patterns
confirm the influence of diagnostic anticipation and/or
improvements over the last decade [9,11]. These changes
in incidence can be compared with data on number of
Table 4. Observed and relative survival rates (%) for prostate cancer by age and calendar period. Vaud and Neuchatel, Switzerland, 1974-1994.
Age
group(years)
<65
65-74
>75
All ages
Survival
Observed
Relative
Observed
Relative
Observed
Relative
Observed
Relative
Calendar period
1974-1979
2-year
67.9
71.2
67.6
73.1
55.6
66.5
62.4
70.0
5-year
38.5 (2.2)a
44.5
37.7(2.5)
47.2
27.3 (2.2)
45.1
26.4(1.6)
45.9
10-year
16.0
25.3
14.7
25.6
8.5
29.1
12.7
26.4
1980-1984
2-year
69.2
74.3
68.3
74.1
55.4
66.8
62.5
70.8
5-year
44.0 (2.3)
47.6
44.2 (2.7)
55.5
25.4(2.1)
42.7
34.9(1.6)
49.0
10-year
17.6
27.1
16.5
29.0
7.9
24.8
12.5
27.3
1985-1989
2-year
80.2
84.7
79.5
86.2
59.7
71.8
69.4
78.7
5-year
51.1(2.1)
61.2
49.2 (2.5)
61.7
27.9(1.8)
46.8
38.9(1.4)
54.8
10-year
29.2
44.3
26.9
47.7
10.0
35.1
19.1
42.2
1990-1994
2-year
77.3
84.9
75.6
81.7
60.5
72.6
68.5
77.6
5-year
53.8(3.0)
65.5
51.7(2.8)
64.3
30.1 (2.7)
50.2
41.4(2.1)
58.2
1
 Standard deviation is given in parentheses.
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Figure 1. Trends in three-year age-standardized (world population) incidence and mortality rates of prostate cancer, and of the number of
PSA tests performed. Vaud and Neuchatel Cantons, Switzerland, 1974-1994.
PSA tests from major (public and private) laboratories
in the Cantons of Vaud and Neuchatel. PSA testing was
introduced in 1989, reaching levels of 12,000 PSA tests
per year in 1995 and 1996. Thus, even in the absence of
any organized screening program, it can be estimated
that in the early 1990s at least 10% of men aged 65 or
more in the study areas may have undergone PSA testing.
Although no reliable data on indication are available, a
large proportion of these tests are likely to be for screen-
ing, rather than diagnosis or follow-up purposes. Still,
such percentage is approximately half as that estimated
in some areas of the US [4]. However, since the increase
in prostatic cancer incidence precedes in part the spread
of PSA testing, it is clear that other factors had been
already operating in the 1980s, including the increase in
the number of biopsies and TURP for prostatic benign
hyperplasia, and the relatively frequent practice of rectal
examination. In 1992-1993, for instance, in the Canton
of Vaud 17% of men aged 50-64 and 27% of those aged
65 or more years reported to have had rectal examina-
tion in the previous 12 months [30].
Still, while Swiss prostatic cancer mortality rates
are the highest in the world (i.e., 22 per 100,000 vs. 17
per 100,000 in the US, all races combined, in 1988-
1992), incidence rates are still considerably lower than
those of North America (i.e., 47 per 100,000 in Vaud and
Neuchatel versus 102 per 100,000 in the US) [20]. A
marked gap also persists with respect to prostate cancer
survival, despite the reported improvements. Five-year
relative survival rates in cases diagnosed between 1986
and 1991 were in the US 86% for all races and 88% for
white males, as compared to about 58% in Vaud and
Neuchatel. Survival rates in this study are, however,
similar to those reported (about 60%) in the late 1980s
in Sweden, overall and in specific age groups [14, 21, 22].
It is therefore likely that the rise in prostatic cancer
incidence will continue in the near future in this popula-
tion where PSA screening is in an earlier phase than in
North America, while a reversal of trends is already
evident in the US [11]. The traditionally high mortality
rates of prostatic cancer in Switzerland provides also a
privileged context in order to assess any favourable
impact of diagnostic improvements.
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